These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26912452)

  • 21. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming cancer resistance.
    Cook KL; Clarke R
    Future Med Chem; 2015 Aug; 7(12):1471. PubMed ID: 26334204
    [No Abstract]   [Full Text] [Related]  

  • 24. Novel next-generation sequencing and networks-based therapeutic targets: realistic and more effective drug design and discovery.
    Roukos DH; Baltogiannis GG; Katsouras CS; Bechlioulis A; Naka KK; Batsis C; Liakakos T; Michalis LK
    Curr Pharm Des; 2014; 20(1):11-22. PubMed ID: 23530498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategy of Daiichi Sankyo discovery research in oncology.
    Akahane K; Hirokawa K
    Jpn J Clin Oncol; 2014 Feb; 44(2):109-15. PubMed ID: 24459194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapy: overcoming drug resistance with clinical cancer genome.
    Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
    [No Abstract]   [Full Text] [Related]  

  • 28. Successes and limitations of targeted cancer therapy in breast cancer.
    Curigliano G; Criscitiello C
    Prog Tumor Res; 2014; 41():15-35. PubMed ID: 24727984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerating safe drug development: an ideal approach to approval.
    Grever MR
    Hematology Am Soc Hematol Educ Program; 2013; 2013():24-9. PubMed ID: 24319158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
    Kruglyak KM; Lin E; Ong FS
    Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision cancer medicine: where to target?
    Yu Q; Ding J
    Acta Pharmacol Sin; 2015 Oct; 36(10):1161-2. PubMed ID: 26388154
    [No Abstract]   [Full Text] [Related]  

  • 32. From standard to new genome-based therapy of gastric cancer.
    Lianos GD; Mangano A; Cho WC; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2015; 9(8):1023-6. PubMed ID: 26108988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibody-based therapies in cancer: advances and challenges.
    Sapra P; Shor B
    Pharmacol Ther; 2013 Jun; 138(3):452-69. PubMed ID: 23507041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Precision medicine from experimental to clinical applications in oncology].
    Normanno N
    Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual or multi-targeting inhibitors: The next generation anticancer agents.
    Raghavendra NM; Pingili D; Kadasi S; Mettu A; Prasad SVUM
    Eur J Med Chem; 2018 Jan; 143():1277-1300. PubMed ID: 29126724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epistatic interactions and drug response.
    Weigelt B; Reis-Filho JS
    J Pathol; 2014 Jan; 232(2):255-63. PubMed ID: 24105606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision Oncology: The Road Ahead.
    Senft D; Leiserson MDM; Ruppin E; Ronai ZA
    Trends Mol Med; 2017 Oct; 23(10):874-898. PubMed ID: 28887051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New frontiers in therapeutic resistance in cancer.
    Sartore-Bianchi A; Delorenzi M; Gagnon-Kugler T; Rousseau C; Batist G
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):877-9. PubMed ID: 22845402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting autophagy to overcome drug resistance in cancer therapy.
    Kumar A; Singh UK; Chaudhary A
    Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
    Izar B; Rotow J; Gainor J; Clark J; Chabner B
    Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.